Spin-off of Kagoshima University developing oncolytic viruses (Surv.m-CRA series) with a survivin promoter.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series B Serve Biopharma raised 670 million yen in the second close of its Series B (2.17 billion cumulative) from Kyoto University Innovation Capital, Toho Holdings and others. | $4.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.